• ImmunityBio announced that ANKTIVA (nogapendekin alfa inbakicept) is now commercially available in Saudi Arabia for BCG-unresponsive non-muscle invasive bladder cancer and, under accelerated approval, in combination with checkpoint inhibitors for metastatic non-small cell lung cancer.
• This commercial rollout, supported by local partners Biopharma and Cigalah Healthcare, extends ANKTIVA’s reach into a region with a growing burden of bladder and lung cancers and follows a series of recent regulatory authorizations across the U.S., U.K., EU, Macau, and Saudi Arabia.
• We’ll now examine how ANKTIVA’s Saudi launch across bladder and lung cancer indications could influence ImmunityBio’s broader investment narrative and outlook.

Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

ImmunityBio Investment Narrative Recap

To own ImmunityBio, you have to believe ANKTIVA can move from a single core bladder cancer product to a broader, multi indication franchise in real clinical use. The Saudi launch adds another real world test of that thesis, but it does not change the near term focus on U.S. and EU bladder cancer uptake and the key risk that ANKTIVA remains concentrated in one primary indication if other programs or geographies scale more slowly than hoped.

Among recent developments, the European Commission’s conditional marketing authorization for ANKTIVA plus BCG across 33 EU countries looks most connected to the Saudi news. Both highlight that the company is now executing on a multi region rollout, with partners like Accord in Europe and Biopharma and Cigalah in Saudi Arabia, which ties directly into the catalyst of expanding the treated patient base and the risk that adoption and reimbursement vary sharply by market.

Yet investors should also weigh the risk that, despite growing approvals, ANKTIVA’s real world adoption outside the U.S. could remain concentrated in a few geographies and...

ImmunityBio's narrative projects $1.2 billion revenue and $435.5 million earnings by 2029. This requires 118.9% yearly revenue growth and a $786.9 million earnings increase from $-351.4 million today.

Uncover how ImmunityBio's forecasts yield a $13.50 fair value, a 85% upside to its current price.

Exploring Other Perspectives

Before this Saudi launch, the most optimistic analysts were already assuming revenue could reach about US$1.6 billion by 2029, which is far more ambitious than the consensus view. If you think about how dependent that outlook is on broad international uptake and not just U.S. use, this new market entry could eventually shift both bullish and baseline narratives in different ways.

Explore 9 other fair value estimates on ImmunityBio - why the stock might be worth over 4x more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your ImmunityBio research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free ImmunityBio research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate ImmunityBio's overall financial health at a glance.

No Opportunity In ImmunityBio?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.
• Outshine the giants: these 18 early-stage AI stocks could fund your retirement.
• The latest GPUs need a type of rare earth metal called Neodymium and there are only 32 companies in the world exploring or producing it. Find the list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.